← All tickers

Is CADL Worth Buying in 2026?

Candel Therapeutics, Inc. Common Stock

STOCK BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) Updated 2026-08-16

Here’s whether Candel Therapeutics, Inc. Common Stock (CADL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bullish.

🟢
Bullish

Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+5.64% over 10 days); strong 1-year return of +94.0%; 3-month momentum positive (+33.6%). Concerns: RSI 77 — overbought, elevated pullback risk. Currently 1.9% off its 52-week high. Score: +5/7.

Ready to act on this? 📈 Trade on Webull

CADL is in a confirmed uptrend, trading above both its 50-day ($9.67) and 200-day ($6.80) moving averages. With an RSI of 76.5, momentum has stretched into overbought territory — short-term pullbacks are common from these levels. The 1-year return of +94.0% compares to +20.4% for SPY (beat the market by 73.7%).

$10,000 invested 1 year ago → $19,404 today
vs. S&P 500 (SPY) — same period beat market by 73.7%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

✓Above 200-day MA ($6.80)
✓Above 50-day MA ($9.67)
!RSI(14) neutral zone (30–70) — currently 76.5
✓Positive return (+94.0%)
✓Within 10% of period high (−1.9%)
Period Range $11.72
$4.35 $11.95
RSI (14) 76.5
0 · OversoldOverbought · 100

Key Metrics

Price$11.72
Period Return+94.0%
Period High$11.95
Period Low$4.35
Drawdown−1.9%
MA-50$9.67
MA-200$6.80
RSI (14)76.5
Avg Volume (30d)1.3M
vs. SPYbeat by 73.7%
Return Rank#164 of 1252

Trade CADL

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers